Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $3.21 to $20, according to analysts polled by Capital IQ. (MT...
Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $3.21 to $20, according to analysts polled by Capital IQ. (MT...
Homology Medicines (FIXX) said Monday that the US Food and Drug Administration has lifted a clinical hold on a trial of the company's HMI-102...
Homology Medicines (FIXX) has an average rating of outperform and price targets ranging from $4 to $29, according to analysts polled by Capital IQ. (MT...
| Address | One Patriots Park Bedford, Massachusetts 01730 |
| Phone | +1.781.301.7277 |
| Number of Employees | 124 |
| Recent SEC Filing | 08/15/2022 10-Q |
| Chief Executive Officer & Director | Arthur O. Tzianabos |
| President & Chief Scientific Officer | Albert Seymour |
| Senior VP, Head-Clinical Development & Operations | Julie Jordan |
| Treasurer, Chief Financial & Business Officer | W. Bradford Smith |
| Price Open | $2.68 |
| Previous Close | $2.68 |
| 52 Week Range | $1.30 - 8.90 |
| Market Capitalization | $141.8 M |
| Shares Outstanding | 57.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/21/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.07 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.7 M |
| Net Profit Margin | -47.29% |
| Return on Equity | -1.20% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
